Press Releases
Press Releases
-
April 15, 2021
Gilead Sciences to Release First Quarter 2021 Financial Results on Thursday, April 29, 2021 -
April 13, 2021
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer -
April 7, 2021
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival -
April 1, 2021
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia -
March 31, 2021
Gilead Sciences Comments on the Passing of John C. Martin, PhD -
March 26, 2021
Gilead Sciences Appoints Flavius Martin, MD as Executive Vice President, Research -
March 25, 2021
European Medicines Agency Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer -
March 18, 2021
Gilead and Novo Nordisk Expand NASH Clinical Collaboration -
March 15, 2021
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV -
March 9, 2021
Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI